Qlife Holding's Blood Testing Platform Selected for AI-driven Diabetes Study in China

05:34 AM EST, 12/12/2025 (MT Newswires) -- Qlife Holding (QLIFE.ST) said its Egoo Health blood testing platform was selected for an AI-driven personalized diabetes management project in China. The joint project by Hipro Biotechnology Co. and Beijing Tsinghua Changgung Hospital is a performance evaluation study that will use the Egoo HbA1c test for patients, according to a Friday release. Qlife Holding noted that the test is not yet approved for sales. It intends to use the results from the study in its filing for regulatory approval.